These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10982111)

  • 1. Improving value measurement in cost-effectiveness analysis.
    Ubel PA; Nord E; Gold M; Menzel P; Prades JL; Richardson J
    Med Care; 2000 Sep; 38(9):892-901. PubMed ID: 10982111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating QALYs with a heavy dose of social values: is the cure worth the cost?
    Matchar DB
    Med Care; 2000 Sep; 38(9):889-91. PubMed ID: 10982110
    [No Abstract]   [Full Text] [Related]  

  • 3. Double jeopardy and the use of QALYs in health care allocation.
    Singer P; McKie J; Kuhse H; Richardson J
    J Med Ethics; 1995 Jun; 21(3):144-50. PubMed ID: 7674278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating societal concerns for fairness in numerical valuations of health programmes.
    Nord E; Pinto JL; Richardson J; Menzel P; Ubel P
    Health Econ; 1999 Feb; 8(1):25-39. PubMed ID: 10082141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morality and the limits of societal values in health care allocation.
    Walker RL; Siegel AW
    Health Econ; 2002 Apr; 11(3):265-73. PubMed ID: 11921322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?
    Mansley EC; Elbasha EH
    Health Econ; 2003 Mar; 12(3):187-98. PubMed ID: 12605464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-saving treatments and disabilities. Are all QALYs created equal?
    Ubel PA; Richardson J; Prades JL
    Int J Technol Assess Health Care; 1999; 15(4):738-48. PubMed ID: 10645115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QALYs, standard gambles, and the expected budget constraint.
    Blomqvist A
    J Health Econ; 2002 Mar; 21(2):181-95. PubMed ID: 11939237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the value of treating schizophrenia?
    Carr VJ; Lewin TJ; Neil AL
    Aust N Z J Psychiatry; 2006; 40(11-12):963-71. PubMed ID: 17054564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
    Feng X; Kim DD; Cohen JT; Neumann PJ; Ollendorf DA
    Int J Technol Assess Health Care; 2020 Apr; 36(2):96-103. PubMed ID: 32340631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impartiality and disability discrimination.
    Bognar G
    Kennedy Inst Ethics J; 2011 Mar; 21(1):1-23. PubMed ID: 21598844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discounting life-years: whither time preference?
    Gyrd-Hansen D; Søgaard J
    Health Econ; 1998 Mar; 7(2):121-7. PubMed ID: 9565168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of order effects in person trade-off elicitations.
    Ubel PA; Richardson J; Baron J
    Health Policy; 2002 Aug; 61(2):189-99. PubMed ID: 12088891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The social value of health programmes: is age a relevant factor?
    Rodríguez E; Pinto JL
    Health Econ; 2000 Oct; 9(7):611-21. PubMed ID: 11103927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis.
    Menzel P; Dolan P; Richardson J; Olsen JA
    Soc Sci Med; 2002 Dec; 55(12):2149-58. PubMed ID: 12409128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.